

8 May 2014 EMA/242696/2014 Veterinary Medicines Division

Monthly report on application procedures, guidelines and related documents for veterinary medicines April 2014

This report, which is updated every month, provides current information related to the volume and evaluation of pre- and post-authorisation applications for medicinal products for veterinary use received by the European Medicines Agency (EMA) for the current and previous three years on:

- scientific-advice requests;
- applications for initial evaluations, variations, extensions and renewals concerning marketing authorisations (MAs);
- applications for initial evaluations, extensions, modifications and extrapolations for maximum residue limits (MRLs);
- arbitration and referral procedures;
- requests for classification of products as Minor Use/Minor Species (MUMS)/limited market.

In addition, the report includes a summary table of the opinions issued by the Committee for Medicinal Products for Veterinary Use (CVMP) in the current year, as well as a list of adopted guidelines and other public guidance documents.

The purpose is only to provide ongoing factual information. Commentaries and analysis are provided in the Agency's annual reports.




An agency of the European Union


Statistics on pre- and post-authorisation applications for medicinal products for veterinary use

Scientific-advice requests					
	2011	2012	2013	2014	
Submitted	26	28	40	8	
Advice given	23	29	34	15	






Initial evaluation of marketing-authorisation applications					
	2011	2012	2013	2014	
Full (submitted)	8	12	23	4	
Abridged/generics (submitted)	3	0	0	1	
Withdrawals	0	1	0	0	
Positive opinions	19	9	12	6	
Negative opinions	0	0	0	0	





Pre-authorisation: outcome of the evaluation of MA applications




Monthly report on application procedures, guidelines and related documents for veterinary medicines EMA/242696/2014

Marketing authorisations					
	2011	2012	2013	2014	
Granted	24	8	13	5	
Withdrawals	1	3	3	0	
Not renewed	0	0	0	0	

Extensions – applications					
	2011	2012	2013	2014	
Submitted	7	8	5	1	
Withdrawals	0	1	0	1	
Positive opinions	4	10	9	1	
Negative opinions	0	0	0	0	

Variations – applications submitted					
	2011	2012	2013	2014	
Type-IA variations	120	104	175	55	
Type-IB variations	101	96	108	39	
Type-II variations	45	52	32	18	
Transfers	3	2	24	1	

Post-authorisation: variations and transfers submitted



Renewals — applications					
	2011	2012	2013	2014	
Submitted	14	10	16	7	
Positive opinions	12	10	14	8	
Negative opinions	0	0	0	0	


Establishment of MRLs for new substances — applications						
2011 2012 2013 2014						
Submitted	1	1	7	2		
Withdrawals	0	1	1	0		
Positive opinions ¹	4	1	4	1		
Negative opinions	0	0	0	0		

¹ Including opinions recommending the extension of the expiry date for provisional MRLs or definitive MRLs for substances with previously provisional MRLs.

Extensions/modifications/extrapolations of MRLs – applications						
2011 2012 2013 2014						
Submitted	13	5	6	1		
Withdrawals	2	0	0	0		
Positive opinions ²	12	8 (2)	8	0		
Negative opinions	0	0	0	0		

² Including opinions recommending the extension of the expiry date for provisional MRLs or definitive MRLs for substances with previously provisional MRLs. Re-examination of opinions are indicated in brackets.

Substances considered as not falling within the scope of Regulation (EC) No $470/2009 -$ requests					
	2011	2012	2013	2014	
Submitted	5	9	16	3	
Agreed	10	6	9	3	
Not agreed	0	1	2	0	
Scientific advice recommended	0	0	6	0	



MRL-related submissions

MUMS/limited-market classification — requests					
	2011	2012	2013	2014	
Positive with financial incentives	8	16	10	1	
Positive without financial incentives	10	4	10	6	
Negative	3	1	3	1	




Positive with financial incentives Positive without financial incentives Negative

Arbitrations and referrals

	2011	2012	2013	2014
Arbitrations and referrals submitted	12	12	10	3
Opinions ³	10 (1)	11 (1)	13 (3)	4(1)

³ Re-examination of opinions in brackets.



Arbitrations and referrals submitted and opinions

CVMP opinions in 2014 on medicinal products for veterinary use

Positive opinions

Product	Marketing	Therapeutic area	EMA/CVMP	European
 Invented name INN/Common name 	authorisatio n holder	 Target species Summary of indication 	 Validation Opinion Active time Clock stop 	Commission • Opinion received • Transmission to EC • Decision • Notification • Official Journal
 Fungitraxx Itraconazole 	Avimedical B.V	 Ornamental birds Treatment of aspergillosis and candidiasis. 	• 07/11/2012 • 16/01/2014 • 210 • 225	 16/01/2014 12/02/2014 12/03/2014
• Equisolon • Prednisolone	• LE VET B.V.	 Horse Alleviation of clinical recurrent airway obstruction (RAO) in combination with environmental control. 	 10/10/2012 16/01/2014 210 253 	 16/01/2014 12/02/2014 12/03/2014
 Parvoduk Muscovy duck parvovirus 	• MERIAL	 Muscovy duck Vaccine against duck parvovirosis and Derzsy's disease. 	 07/11/2012 13/02/2014 203 260 	 13/02/2014 10/03/2014 11/04/2014
 Versican Plus DHPPi/L4R Canine distemper virus, canine adenovirus, canine parvovirus, canine parainfluenza virus, leptospiras and rabies virus 	• Zoetis Belgium SA	 Dog Vaccine against canine distemper, infectious hepatitis, infectious tracheobronchitis (kennel cough), parvovirus disease, leptospirosis and rabies. 	 20/03/2013 13/03/2014 203 155 	 13/03/2014 09/04/2014
 Versican Plus DHPPi/L4 Canine distemper 	 Zoetis Belgium SA 	DogVaccine against canine	15/05/201313/03/2014210	13/03/201409/04/2014

Monthly report on application procedures, guidelines and related documents for veterinary medicines $\mathsf{EMA}/\mathsf{242696}/\mathsf{2014}$

ProductInvented nameINN/Common name	Marketing authorisatio n holder	Therapeutic areaTarget speciesSummary of indication	EMA/CVMP • Validation • Opinion • Active time • Clock stop	European Commission • Opinion received • Transmission to EC • Decision • Notification • Official Journal
virus, canine adenovirus, canine parvovirus, canine parainfluenza virus and leptospiras		distemper, infectious hepatitis, infectious tracheobronchitis (kennel cough), parvovirus disease and leptospirosis.	• 92	
 Vectra Felis Dinotefuran, pyriproxyfen 	 Ceva Santé Animale 	 Cats Treatment and prevention of flea infestations. 	 13/12/2012 10/04/2014 210 274 	• 10/04/2014

CVMP opinions in 2014 on establishment of MRLs

Positive opinions

Product	Target species	EMA/CVMP	European Commission
Substance		 Validation Opinion Active time Clock stop 	 Opinion received Decision Notification Official Journal
• Barium selenate	 All food producing species 	• N/a • 10/04/2014 • 130 • N/a	• 11/04/2014

Arbitrations and referrals in 2014

Ongoing procedures

Type of procedure	Date • Clock start	Product Product name
	CVMP opinion	• INN
Referral under Article 35 of Directive 2001/82/EC	• 12/09/2012	 Suanovil 20 and associated names, Captalin and associated names and generic products thereof, including pending applications Spiramycin
Referral under Article 34 of Directive 2001/82/EC	10/10/201210/04/2014	 Linco-Spectin 100 and its associated names Lincomycin, spectinomycin
Referral under Article 34 of Directive 2001/82/EC	07/11/201209/04/2014	 Baytril 2.5% injectable, Baytril 5% injectable and Baytril 10% injectable and their associated names Enrofloxacin
 Referral under Article 30(3) of Regulation 726/2004 	• 10/01/2013	LidocaineLidocaine
Referral under Article 35 of Directive 2001/82/EC	• 10/04/2013	 All veterinary medicinal products containing altrenogest to be administered orally to pigs and horses Altrenogest
Referral under Article 35 of Directive 2001/82/EC	16/05/201309/04/2014	 Baytril 2.5% injectable, Baytril 5% injectable, Baytril 10% injectable and associated names and related veterinary medicinal products authorised under Article 13 of Directive 2001/82/EC Enrofloxacin

Type of procedure	Date • Clock start • CVMP opinion	Product • Product name • INN
Referral under Article 35 of Directive 2001/82/EC	• 06/11/2013	 All veterinary medicinal products containing tylosin to be administered orally via feed or the drinking water to pigs Tylosin
 Referral under Article 33(4) of Directive 2001/82/EC 	16/05/201315/01/2014	 Norbonex 5-mg/ml pour-on solution for beef and dairy cattle Eprinomectin
Referral under Article 33(4) Directive 2001/82/EC	 16/05/2013 11/12/2013 09/04/2014 (re-examination) 	 Fiprex CAT 52.5 mg spot-on solution for cats, Fiprex S 75 mg spot-on solution for dogs, Fiprex M 150 mg spot-on solution for dogs, Fiprex L 300 mg spot-on solution for dogs and Fiprex XL 412.5 mg spot-on solution for dogs Fipronil
 Referral under Article 13 of Regulation (EC) No. 1234/2008 	• 12/02/2014	Resflor solution injectableFlorfenicol, flunixin
 Referral under Article 13 of Regulation (EC) No. 1234/2008 	• 12/02/2014	 Ubrolexin intramammary suspension for lactating dairy cows Cephalexin, kanamycin
Referral under Article 35 of Directive 2001/82/EC	• 12/03/2014	 All veterinary medicinal products containing gentamicin presented as solutions for injection to be administered in horses Gentamicin

Guidelines and working documents in 2014

CVMP quality

Reference number	Document title	Status
EMA/CHMP/CVMP/QWP/70278/20 12-Rev.1	Guideline on process validation for finished products. Information and data to be provided in regulatory submissions.	Adopted January 2014 (End of consultation 31 October 2012)
EMA/CHMP/CVMP/QWP/441071/2 011	Guideline on stability testing for applications for variations to a marketing authorisation.	Adopted January 2014 (End of consultation 31 January 2012)
[Published on EMA website]	Revised Q&A on limits for microbiological quality for premixes for medicated feeding stuffs which contain excipients of natural origin.	Adopted January 2014
EMEA/CHMP/CVMP/QWP/80360/2 014	Joint CHMP/CVMP template and guidance notes for the Qualified Person's declaration concerning GMP compliance of the active substance and verification of its supply chain.	Adopted March 2014
EMEA/CHMP/CVMP/QWP/63700/2 014	Joint CHMP/CVMP revised guideline on the use of near infrared spectroscopy (NIRS) by the pharmaceutical industry and the data requirements for new submissions and variations.	Adopted March 2014 (End of consultation 31 August 2009)
EMA/CHMP/CVMP/QWP/53392/20 14	Joint CHMP/CVMP concept paper for the establishment of a guideline on the selection of sterilisation processes for drug products.	Adopted for consultation, March 2014 (End of consultation 30 June 2014)
[Published on EMA website]	Q&A on limits for unspecified impurities for active substances used in veterinary medicinal products.	Adopted March 2014
[Published on EMA website]	Q&A on the stability of generics versus the innovator product.	Adopted March 2014
[Published on EMA website]	Q&A on the acceptability of two different appearances for a single strength tablet in a single marketing authorisation.	Adopted April 2014

Reference number	Document title	Status
[Published on EMA website]	Q&A on Particles originating from the container-closure system.	Adopted April 2014

CVMP safety

Reference number	Document title	Status
EMA/CVMP/SWP/529692/2013	Draft concept paper on user risk assessment of topically applied products	Adopted for consultation, March 2014 (End consultation 30 June 2014)

CVMP efficacy

Reference number	Document title	Status
EMA/CVMP/EWP/513162/2013	Guideline on for the conduct of efficacy studies for non-steroidal anti-inflammatory drugs (NSAID) (Revised).	Adopted January 2014 (End of consultation 31 May 2013)
EMA/CVMP/EWP/573536/2013	Draft reflection paper on anthelmintic resistance	Adopted for consultation, April 2014 (End of consultation 31 July 2014)

CVMP Pharmacovigilance

Reference number	Document title	Status
EMA/781698/2013	Public bulletin on veterinary	Adopted March 2014
	pharmacovigilance for 2013.	

Antimicrobials

Reference number	Document title	Status
EMA/CVMP/AWP/119489/2012- Rev.1)	Reflection paper on the use of pleuromutilins in food-producing animals in the European Union: development of resistance and impact on human and animal health (Revised).	Adopted February 2014

General

Reference number	Document title	Status
EMA/CVMP/VICH/758781/2013	Draft VICH GL53 on electronic exchange of documents: file format requirements – 6 months public consultation.	Adopted for consultation, February 2014 (End of consultation 20 July 2014)